Castle Biosciences, Inc.
CSTL
$25.62
-$0.29-1.10%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 3.66% | 10.15% | 20.40% | 38.43% | 51.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.66% | 10.15% | 20.40% | 38.43% | 51.09% |
| Cost of Revenue | 17.98% | 22.06% | 26.16% | 28.75% | 33.84% |
| Gross Profit | 0.49% | 7.52% | 19.13% | 40.77% | 55.52% |
| SG&A Expenses | 14.63% | 14.62% | 15.33% | 15.55% | 11.04% |
| Depreciation & Amortization | 213.69% | 308.34% | 308.30% | 311.42% | 23.22% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.68% | 20.95% | 21.75% | 23.31% | 12.38% |
| Operating Income | -593.77% | -3,265.41% | -46.28% | 67.12% | 112.75% |
| Income Before Tax | -236.87% | -269.82% | -155.09% | 92.77% | 137.59% |
| Income Tax Expenses | -261.37% | -231.92% | 14.92% | 2,059.85% | 3,186.14% |
| Earnings from Continuing Operations | -232.41% | -301.42% | -205.45% | 83.54% | 131.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -232.41% | -301.42% | -205.45% | 83.54% | 131.75% |
| EBIT | -593.77% | -3,265.41% | -46.28% | 67.12% | 112.75% |
| EBITDA | -100.91% | -22.32% | 827.70% | 198.24% | 144.33% |
| EPS Basic | -229.22% | -295.43% | -165.63% | 86.20% | 130.33% |
| Normalized Basic EPS | -243.40% | -298.35% | -129.12% | 97.80% | 135.03% |
| EPS Diluted | -239.40% | -326.98% | -161.19% | 82.66% | 128.36% |
| Normalized Diluted EPS | -252.27% | -317.10% | -133.75% | 93.91% | 132.96% |
| Average Basic Shares Outstanding | 4.35% | 4.29% | 4.12% | 3.83% | 3.63% |
| Average Diluted Shares Outstanding | 0.64% | 4.24% | 6.97% | 8.20% | 8.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |